Towards consensus practices to qualify safety biomarkers for use in early drug development

Application of any new biomarker to support safety-related decisions during regulated phases of drug development requires provision of a substantial data set that critically assesses analytical and biological performance of that biomarker. Such an approach enables stakeholders from industry and regu...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2010-05, Vol.28 (5), p.446-454
Main Authors: Sistare, Frank D, Dieterle, Frank, Troth, Sean, Holder, Daniel J, Gerhold, David, Andrews-Cleavenger, Dina, Baer, William, Betton, Graham, Bounous, Denise, Carl, Kevin, Collins, Nathaniel, Goering, Peter, Goodsaid, Federico, Gu, Yi-Zhong, Guilpin, Valerie, Harpur, Ernie, Hassan, Alita, Jacobson-Kram, David, Kasper, Peter, Laurie, David, Lima, Beatriz Silva, Maciulaitis, Romaldas, Mattes, William, Maurer, Gérard, Obert, Leslie Ann, Ozer, Josef, Papaluca-Amati, Marisa, Phillips, Jonathan A, Pinches, Mark, Schipper, Matthew J, Thompson, Karol L, Vamvakas, Spiros, Vidal, Jean-Marc, Vonderscher, Jacky, Walker, Elizabeth, Webb, Craig, Yu, Yan
Format: Article
Language:English
Subjects:
631/154/53
692/308/153
692/699/1585/4
Agriculture
Animals
Bioinformatics
Biological markers
Biomarkers
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Biotechnology industry
Drug Discovery - legislation & jurisprudence
Drug Discovery - methods
Drug-Related Side Effects and Adverse Reactions
Drugs
Humans
Life Sciences
perspective
Pharmaceutical industry
Pharmaceutical Preparations - standards
Product development
Product/Service Evaluations
Safety
Stakeholders
Standardization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Application of any new biomarker to support safety-related decisions during regulated phases of drug development requires provision of a substantial data set that critically assesses analytical and biological performance of that biomarker. Such an approach enables stakeholders from industry and regulatory bodies to objectively evaluate whether superior standards of performance have been met and whether specific claims of fit-for-purpose use are supported. It is therefore important during the biomarker evaluation process that stakeholders seek agreement on which critical experiments are needed to test that a biomarker meets specific performance claims, how new biomarker and traditional comparators will be measured and how the resulting data will be merged, analyzed and interpreted.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.1634